Rybelsus®

Semaglutide

Rybelsus® tablets (semaglutide) is a prescription medicine used in adults with type 2 diabetes mellitus to decrease blood sugar levels. Rybelsus® can be prescribed when other diabetes medicines have been tried without success and should be used together with diet and exercise. Rybelsus® tablets work to lower blood sugar (glucose) levels by increasing how much insulin is released and decreasing glucagon secretion. This medicine also may slow gastric emptying after eating.
more
Package Per pill Price Savings Order
90 tablet
Free AirMail shipping Hot
lei 69.45
lei 6250.54lei 69.45
lei 832.97
60 tablet
Free AirMail shipping Hot
lei 74.08
lei 4444.76lei 74.08
lei 277.58
30 tablet
Free AirMail shipping Hot
lei 78.71
lei 2361.17lei 78.71
Package Per pill Price Savings Order
90 tablet
Free AirMail shipping Hot
lei 83.34
lei 7500.69lei 83.34
lei 416.25
60 tablet
Free AirMail shipping Hot
lei 85.65
lei 5139.29lei 85.65
lei 138.67
30 tablet
Free AirMail shipping Hot
lei 87.97
lei 2638.98lei 87.97
Package Per pill Price Savings Order
90 tablet
Free AirMail shipping Hot
lei 99.55
lei 8959.21lei 99.55
lei 416.25
60 tablet
Free AirMail shipping Hot
lei 101.86
lei 6111.63lei 101.86
lei 138.67
30 tablet
Free AirMail shipping Hot
lei 104.17
lei 3125.15lei 104.17
Rybelsus

Brand(s)

Manufacturer

  • Novo Nordisc India Pvt. Ltd

Disease(s)

  • Type 2 Diabetes Mellitus / High Blood Sugar

Rybelsus® tablets

What is Rybelsus?

Rybelsus tablets (semaglutide) is a prescription medicine used in adults with type 2 diabetes mellitus to decrease blood sugar levels. Rybelsus can be prescribed when other diabetes medicines have been tried without success, and should be used together with diet and exercise.

Rybelsus tablets work to lower blood sugar (glucose) levels by increasing how much insulin is released and decreasing glucagon secretion. This medicine also may slow gastric emptying after eating. Rybelsus is from the class of medicines called GLP-1 receptor agonists.
Rybelsus is not for treating type 1 diabetes.
Rybelsus was first approved by the FDA on September 20, 2019.

Warnings

You should not use Rybelsus if you have multiple endocrine neoplasia type 2 (tumors in your glands), a personal or family history of medullary thyroid cancer, insulin-dependent diabetes, or diabetic ketoacidosis.
Call your doctor at once if you have signs of a thyroid tumor, such as swelling or a lump in your neck, trouble swallowing, a hoarse voice, or shortness of breath.